NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: THEMISMED · data 2026-10-30
Themis Medicare Limited
In plain words
Price: 32.6% below its 52-week high of ₹140.6.
Delivery: 41.9% of traded shares were kept for delivery over the last 10 sessions, against 46.5% over the last 60.
Latest results: a net profit of ₹10 cr for the quarter ended Dec 2025.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹332 cr |
| Net profit (last 12 months) | ₹40 cr |
| Sales growth, 3 years (yearly) | -1.2% |
| Profit growth, 3 years (yearly) | -72.8% |
At a glance
Promoters 67.2%, pledged 2.4%, institutions 0.1%.
P/E 21.9, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 0.3%, ROCE -2.3%, operating margin -15.8%: how much profit it earns on the money it uses.
Debt/equity 0.25, Profit growth -72.8% and sales growth -1.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (0.3%).
- Thin operating margin (-15.8%).
- Profit fell 72.8% a year over 3 years.
- Promoters have pledged 2.4% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q4 FY26)
THEMISMED Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹76.53 crore.
Net profit was ₹8.89 crore.
Operating margin was 4.9%.
EPS was ₹0.96.
THEMISMED के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹76.53 करोड़।
शुद्ध मुनाफ़ा: ₹8.89 करोड़।
ऑपरेटिंग मार्जिन: 4.9%।
EPS: ₹0.96।
THEMISMEDના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹76.53 કરોડ.
ચોખ્ખો નફો: ₹8.89 કરોડ.
ઓપરેટિંગ માર્જિન: 4.9%.
EPS: ₹0.96.
Written from the filed numbers. Not a recommendation.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 44.4% over the last 20 sessions vs 28.6% in the 40 before (1.55x); shares delivered per day 0.3x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Insider ● Results
- 23 Sept 26Dividend Dividend ₹0.5 (ex-date) -3.7% next session
- 5 Aug 26Insider SAST disclosure: CTL Trusteeship Limited acquired 30,00,000 shares -2.3% next session
- 13 Feb 26Results Q3 FY26 results: net profit ₹10.1 cr +0.8% next session
- 13 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -5.2% next session
- 4 Sept 25Dividend Dividend ₹0.5 (ex-date) -2.7% next session
- 20 May 25Results Q4 FY25 results: turned to loss vs a year ago -16.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2025 | ₹90 cr | ₹10 cr | — | 10.9% | 1.1 |
| Sept 2025 | ₹78 cr | ₹-4 cr | -125.3% | -4.0% | -0.39 |
| Mar 2025 | ₹72 cr | ₹-10 cr | -245.5% | -8.1% | -1.05 |
| Sept 2024 | ₹117 cr | ₹14 cr | — | 14.6% | 1.55 |
Shareholding trend
| Holder | Jun 2025 | Mar 2025 |
|---|---|---|
| Promoters | 67.15% | 67.15% |
| Foreign institutions (FII) | 0.10% | 0.14% |
| Domestic institutions (DII) | 0.01% | 0.01% |
| Mutual funds | 0.00% | 0.00% |
| Retail investors | 16.90% | 16.51% |
| Number of shareholders | 19,335 | 17,889 |
Common questions
What was Themis Medicare Limited's latest quarterly profit?
Themis Medicare Limited reported a net profit of ₹10 cr for the quarter ended Dec 2025, on revenue of ₹90 cr.
How much do promoters hold in Themis Medicare Limited?
Promoters held 67.15% of Themis Medicare Limited at the end of Jun 2025, with 2.43% of promoter shares pledged.
Is Themis Medicare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.25.
What is Themis Medicare Limited's P/E ratio?
About 21.9, based on the last 12 months' earnings and a price of ₹94.83 (data 2026-10-30).
What is the 52-week high and low of Themis Medicare Limited?
The 52-week high is ₹140.6 and the 52-week low is ₹64.95.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Themis Medicare Limited | ₹94.83 | ₹898 cr | 21.9 | — | 0.3% | -2.3% | 0.25 | -24.0% |
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Sigachi Industries Limited | ₹26.36 | ₹1,009 cr | 39.7 | — | -14.6% | 6.1% | 0.31 | -29.4% |
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
| Anuh Pharma Limited | ₹87.31 | ₹873 cr | 15.7 | — | 12.1% | 17% | 0 | -1.1% |
Compare THEMISMED with LINCOLN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open THEMISMED in NSE Scanner →